Blue Jet Healthcare Ltd Q4 FY25 Earnings Analysis

Published 11 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹11.2K Cr

Price

591

Market Cap

₹11.2K Cr

P/E Ratio

47.6

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Blue Jet Healthcare Ltd Q4 FY25 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Blue Jet Healthcare Ltd share price analysis?

Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.6 with a market cap of ₹11,190 Cr. Investors should review the full earnings analysis for detailed insights.

Is Blue Jet Healthcare Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Pharmaceuticals & Biotechnology this season

  • Acutaas Chemicals Ltd (Q4 FY25)

    Acutaas Chemicals Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹26,877 Cr, P/

  • Cohance Lifesciences Ltd (Q4 FY25)

    Cohance Lifesciences Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹16,429 Cr,

  • Torrent Pharmaceuticals Ltd (Q4 FY25)

    Torrent Pharmaceuticals Ltd Q4 FY25 quarterly results analysis. India business continues to outperform market growth with 12-13% revenue growth YTD; focus on ca

  • Shilpa Medicare Ltd (Q4 FY25)

    Shilpa Medicare Ltd Q4 FY25 quarterly results analysis. Biologics segment is gaining good traction with multiple licensing opportunities and CDMO contracts cont